PUFA Augmentation in Treatment of Major Depression

Completed · Phase 3

Conditions studied: Major Depression

In brief

The purpose of this study is to determine if omega-3 fatty acid EPA will enhance and speed up response to antidepressant therapy with Celexa (Citalopram) in people suffering from Major Depressive Disorder. All patients will receive Celexa, 50% will receive EPA, 50% placebo EPA.

Key facts

Study ID

NCT00067301

Run by

National Center for Complementary and Integrative Health (NCCIH)

People needed

60

Starts

2003-09-01

Expected to finish

2007-04-01

Last updated by the study team

2008-01-25

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Meet DSM-IV criteria for current major depression, and have a HAM-D (21 item) score of > 17
• Male or female who, if of child-bearing potential, agrees to use effective contraception including the regular use of contraceptive pills, intra-uterine devices, barrier methods or abstinence
• Age between 18 and 65
• Capable of giving informed consent

You may not qualify if…

• Diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, schizotypal disorder, psychotic depression or bipolar disorders
• Current drug or alcohol abuse or dependence, or history of drug or alcohol abuse or dependence within the previous 6 months
• Unstable medical or neurological conditions that are likely to interfere with the treatment of depression
• History of allergy to citalopram or ProEPA, finfish or shellfish
• History of failure of response to citalopram, as documented by an adequate trial of the medication [defined as having been treated with the medication at a dose level typically regarded as adequate (i.e., 40 mg of citalopram per day) for at least 6 weeks]
• History of seizure disorder
• Pregnancy
• Currently on psychotropic medications including antidepressants or neuroleptics
• Active suicidal ideation or other safety issues determined by the clinician to not be suitable for inclusion in the study
• Exposure to treatment with fluoxetine or MAOIs in the previous two months
• Patients on anticoagulant therapy
• Patients with a dietary intake of > 3.0g total omega-3 PUFA/day at baseline

Where it is running

• Cedars-Sinai Medical Center Dept. of Psychiatry — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.